

University of Pennsylvania
Office of Regulatory Affairs
3624 Market St., Suite 301 S
Philadelphia, PA 19104-6006
Ph: 215-573-2540/ Fax: 215-573-9438
INSTITUTIONAL REVIEW BOARD
(Federalwide Assurance # 00004028)

20-Sep-2016

Daniel S Herman
Daniel.Herman2@uphs.upenn.edu

PRINCIPAL INVESTIGATOR	: Daniel S Herman
TITLE	: Development of computational strategies for diagnosis, prognosis, and management of cardiovascular disease
SPONSORING AGENCY	: No Sponsor Number
PROTOCOL #	: 825821
REVIEW BOARD	: IRB #7

Dear Dr. Herman:

The above referenced protocol was reviewed and approved using the expedited procedure set forth in 45 CFR 46.110, category 5, on 19-Sep-2016. This study will be due for continuing review on or before 18-Sep-2017.

Approval by the IRB does not necessarily constitute authorization to initiate the conduct of a human subject research study. Principal investigators are responsible for assuring final approval from other applicable school, department, center or institute review committee(s) or boards has been obtained. If any of these committees require changes to the IRB-approved protocol and informed consent/assent document(s), the changes must be submitted to and approved by the IRB prior to beginning the research study.

If this protocol involves cancer research with human subjects, biospecimens, or data, you may not begin the research until you have obtained approval or proof of exemption from the Cancer Center's Clinical Trials Review and Monitoring Committee.

The waiver of informed consent and HIPAA waiver of authorization were reviewed as authorized by 45 CFR 46.116 (d) and 45 CFR 164.512 (i), respectively, and approved on 19-Sep-2016.

An expedited review procedure was used for the HIPAA authorization waiver because the research involves no more than minimal risk to the privacy of the individuals who are the subject of the protected health information for which use or disclosure is being sought.

The protected health information for which use or access has been determined to be necessary is as follows:

Direct identifiers:

-Used/collected:

---Names

---Medical record numbers

-Disclosed:

---No direct identifiers will be disclosed

Indirect identifiers:

-Used/collected:

---Geographic Identifiers such as City/Town and Zip Code [nothing more specific can be included]

---All elements of dates (except year) for dates directly related to an individual (e.g. date of birth/death, dates of admission/discharge etc.)

---Ages less than 90 and a single aggregated category for "90 or older"

-Disclosed:

---No indirect identifiers will be disclosed

Documents submitted for review:

-HS ERA Initial Application, confirmation code: cbjecjbd, submitted 9/14/16

-Response Cover Letter, uploaded 9/14/16

-IRB Request for Waiver of HIPAA Authorization Form, uploaded 8/30/16

The review of the research has determined the following:

- An adequate plan has been presented to protect the identifiers from improper use and disclosure;
- An adequate plan to destroy the identifiers at the earliest opportunity consistent with conduct of the research exists, unless there is a health or research justification for retaining the identifiers, or such retention is otherwise required by law; and,
- An adequate written assurance has been provided that the protected health information will not be reused or disclosed to any other person or entity, except as required by law, for authorized oversight of the research project, or for other research for which the use or disclosure of protected health information would be permitted under the law.
- That the research cannot practicably be conducted without the waiver to access and use of the protected health information.

If you have any questions about the information in this letter, please contact the IRB administrative staff. Contact information is available at our website: <http://www.upenn.edu/IRB/directory>.

Thank you for your cooperation.

Sincerely,

IRB Administrator